National Comprehensive Cancer Network

About NCCN

NCCN ORP Studies and Resources Featured at Recent Conferences

By Donna Scharff, Research Study Associate, NCCN

NCCN IRB Task Force Members Presented Poster on “Points to Consider on the Best Practices for Biorepositories, Registries, and Databases” at the Recent AAHRPP Annual Conference

On May 20, 2015, representatives from a National Comprehensive Cancer Network® (NCCN®) Institutional Review Board (IRB) Directors Forum, Taskforce presented a poster during the 2015 Association for the Accreditation of Human Research Protections Programs, Inc. (AAHRPP) Annual Conference, Looking Back and Looking Forward: Compliance, Collaboration and Community.

Judith Carrithers, JD, MPA, CIP, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and Donald Handley, MSc, MBA, CIP, Roswell Park Cancer Institute, both members of the NCCN IRB Directors Forum Taskforce that developed the resource, presented the poster, which highlights a new tool, Points to Consider on the Best Practices for Biorepositories, Registries, and Databases.

This free resource, launched in April 2015, was developed for use by research investigators who plan to design, implement, and manage research studies that intend to deposit, transfer, and/or access specimens or data in a biorepository, registry or database.

For more information or to access NCCN Points to Consider on the Best Practices for Biorepositories, Registries and Databases, visit NCCN.org.

 

NCCN ORP-Funded Studies Accepted as Posters and Abstracts during the 2015 ASCO Annual Meeting

The following NCCN ORP-funded research studies were accepted as posters during the 2015 ASCO Annual Meeting, May 29 – June 1, 2015, in Chicago, Illinois:

 

The following NCCN ORP-funded research studies will be published during the poster session at the 2015 ASCO Annual Meeting, May 29 – June 1, 2015, in Chicago, Illinois:

  • A Phase II Trial of Pralatrexate (P) Plus Oxaliplatin (O) in Advanced Esophago-Gastric Cancer (aEGC): Survival Analysis and Pharmacogenetic Correlates
  • First Stage Results of a Second Line Phase II Trial of Sorafenib Plus Doxorubicin (SD) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC) Who Progressed on Sorafenib (S)

For more information about NCCN ORP and ongoing clinical studies, visit NCCN.org.